Keith Katkin
CIK: 0001314596
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Apr 30, 2026EBS
Emergent BioSolutions Inc.
Award(A)Direct25.3K shares- - Apr 30, 2026EBS
Emergent BioSolutions Inc.
Sale(S)Direct15.5K shares at avg. $8.28$128K - Feb 4, 2026SNDX
Syndax Pharmaceuticals Inc
Award(A)Direct24K shares- - Jan 10, 2026ELDN
Eledon Pharmaceuticals, Inc.
Exercise(M)Direct8.6K shares- - May 23, 2025EBS
Emergent BioSolutions Inc.
Sale(S)Direct7.8K shares at avg. $6.30$49K - May 19, 2025SNDX
Syndax Pharmaceuticals Inc
Purchase(P)Direct10K shares at avg. $9.11$91K - Apr 30, 2025EBS
Emergent BioSolutions Inc.
Award(A)Direct34.4K shares- - Feb 5, 2025SNDX
Syndax Pharmaceuticals Inc
Award(A)Direct25K shares- - Jan 10, 2025ELDN
Eledon Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
77.2K shares- - Jan 10, 2025ELDN
Eledon Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
8.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 30, 2026 |  EBS Emergent BioSolutions Inc. | Award(A) | 25,344 | - | $0 | Direct |
| Apr 30, 2026 | EBS Emergent BioSolutions Inc. | Sale(S) | 15,481 | $8.28 | $128,183 | Direct |
| Feb 4, 2026 |  SNDX Syndax Pharmaceuticals Inc | Award(A) | 24,000 | - | $0 | Direct |
| Jan 10, 2026 |  ELDN Eledon Pharmaceuticals, Inc. | Exercise(M) | 8,575 | - | $0 | Direct |
| May 23, 2025 | EBS Emergent BioSolutions Inc. | Sale(S) | 7,844 | $6.30 | $49,417 | Direct |
| May 19, 2025 | SNDX Syndax Pharmaceuticals Inc | Purchase(P) | 10,000 | $9.11 | $91,120 | Direct |
| Apr 30, 2025 | EBS Emergent BioSolutions Inc. | Award(A) | 34,403 | - | - | Direct |
| Feb 5, 2025 | SNDX Syndax Pharmaceuticals Inc | Award(A) | 25,000 | - | - | Direct |
| Jan 10, 2025 | ELDN Eledon Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 77,175 | - | - | Direct |
| Jan 10, 2025 | ELDN Eledon Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 8,575 | - | - | Direct |
1-10 of 10 transactions
About Katkin Keith
Katkin Keith (SEC CIK 0001314596) files insider reports with the SEC as Director of Emergent BioSolutions Inc. (EBS), Director of Syndax Pharmaceuticals Inc (SNDX) and Director of Eledon Pharmaceuticals, Inc. (ELDN).
Signal8 holds 8 ownership filings by Katkin Keith, all Form 4s, filed between Jan 13, 2025 and May 4, 2026. Those filings report 10 transactions, from Jan 10, 2025 to Apr 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Katkin Keith's filings is in NEW YORK, NY.
Recent filings by Katkin Keith
- Apr 30, 2026: Grant or award of EBS shares (Form 4, code A).
- Apr 30, 2026: Open-market sale of EBS shares (Form 4, code S).
- Feb 4, 2026: Grant or award of SNDX shares (Form 4, code A).
- Jan 10, 2026: Option exercise of ELDN shares (Form 4, code M).
- May 23, 2025: Open-market sale of EBS shares (Form 4, code S).
Other insiders filing for Emergent BioSolutions Inc. (EBS)
- DeGolyer Donald W, Director
- Williams Paul Anthony, SVP, Products Business
- Duatschek Stephanie, EVP, CGO
- LINDAHL RICHARD S, EVP, Chief Financial Officer
- Glessner Coleen, EVP, Quality & Ethics, and CPL
- Hartzel William, SVP, Bioservices